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Results: During	 follow‐up,	 liver	 malignancy	 incidence	 remained	 stable	 at	 1.1:106. 













tocellular	 carcinoma	 were	 encouraging.	 Adverse	 effects	 of	 chemotherapy	 signifi‐
cantly	contributed	to	mortality.
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1  | INTRODUC TION
Malignant	liver	tumours	are	the	third	most	common	abdominal	ma‐
lignancy	 among	 children,	 accounting	 for	 approximately	 1%	 of	 all	
childhood	solid	tumours.1	The	most	common	paediatric	liver	cancer	
is	hepatoblastoma	(HB)	with	an	incidence	of	1.5	cases	per	million	per	







benign	 mesenchymal	 hamartoma.	 After	 complete	 resection,	 non‐
metastatic‐undifferentiated	 embryonal	 sarcoma	 has	 an	 excellent	
prognosis	in	children.7
Neoadjuvant	 chemotherapy	 followed	 by	 surgical	 resection	 or	
liver	 transplantation	 has	 been	 the	 cornerstone	 of	 childhood	 liver	
malignancy	treatment,	although	very	low‐risk	tumours	can	be	safely	
managed	 with	 upfront	 surgery.2,8	 Unfortunately,	 the	 majority	 of	




tation,	 HCC	 with	 extrahepatic	 disease	 extension	 usually	 remains	




preoperative	 alpha‐fetoprotein	 level,	 presence	 of	 metastases	 and	
radiological	PRETEXT	(PRETreatment	EXTent	of	disease)	staging	are	
essential	determinants	of	prognosis.10
Although	 large	 multicentre	 trials	 have	 improved	 and	 system‐




incidence	of	HB	appears	 to	be	 increasing,13	 and	population‐based	
studies	 are	 needed	 to	 understand	 the	 epidemiology	 of	 paediatric	
malignancies.	 By	 combining	 reliable	 national	 cancer	 registry	 data	




2.1 | Patients and data collection





tumour	 histology,	 cancer	 stage,	 recurrence	 and	 survival	 data	
from	 the	 nationwide	 Finnish	 Cancer	 Registry,	 which	 maintains	
records	 of	 all	 the	 cancer	 patients	 from	 every	medical	 facility	 in	
Finland.	The	Finnish	Cancer	Registry	practically	covers	the	popu‐
lation	 completely	 and	 has	 high	 accuracy.14	 Retrospectively	 col‐
lected	data	from	the	medical	patient	records	included	associated	
diseases,	 imaging	 findings,	 histology	 reports,	 alpha‐fetoprotein	
levels,	 details	 of	 oncological	 and	 surgical	 management,	 adverse	
effects	 and	 surgical	 complications.	 In	 addition,	 height,	 weight	
and	 liver	 biochemistry	 were	 recorded	 at	 last	 follow‐up.	 Causes	






2.2 | Radiological staging and histology
All	patients	underwent	pretreatment	computed	tomography	(CT)	















combinations.17,18	 Patients	 with	 HCC	 received	 cisplatin‐doxoru‐
bicin–based	chemotherapy	with	or	without	sorafenib.	Patients	with	






IV	 hepatoblastoma	 and	 metastasized	 hepatocellular	
carcinoma.
•	 Adverse	 effect	 of	 chemotherapy	 significantly	 contrib‐
uted	to	mortality.
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2.4 | Surgical treatment
Primary	liver	resections	were	mostly	anatomical.	Patients	deemed	
unsuitable	 for	 curative	 resection	 due	 to	 local	 extension,	 central	
tumour	location	or	vascular	invasion	were	evaluated	as	liver	trans‐
plantation	 candidates.	 Unlike	 lung	 metastases	 in	 HB	 resolving	
after	 surgical	 resection	 or	 chemotherapy,	 any	 extrahepatic	HCC	
was	 considered	 as	 a	 contraindication	 for	 liver	 transplantation.	
Rescue	 liver	 transplantation	was	 considered	 in	 case	 of	 local	 re‐
currence	or	residual	disease	after	primary	resection	when	no	dis‐
tant	 metastases	 were	 observed.	 Grafts	 for	 liver	 transplantation	
were	harvested	from	deceased	donors.	Immunosuppression	after	




















were	 analysed	 in	 the	 liver	 transplantation	 group	 unless	 otherwise	
TA B L E  1  Characteristics	of	surgically	treated	patients	according	to	liver	tumour	types
 All patients, n = 42 HB, n = 24 HCC, n = 11 UES, n = 7
Boys,	n	(%) 20	(48) 13	(54) 5	(46) 2	(29)
Age	at	diagnosis,	years 3.5	(1.6‐8.3) 1.7	(0.85‐3.3) 11	(8.3‐14) 5.2	(2.7‐6.6)
AFP	at	diagnosis,	kU/la  49	000	(440‐180	000) 110	000	(59	000‐370	000) 3000	(250‐32	000) 1.0	(1.0‐64)
AFP	at	time	of	primary	surgery,	
kU/lb
150	(9‐2100) 130	(17‐1000) 270	(3‐2400) 1.0	(1.0‐1.0)
PRETEXT,	n	(%)c
I 1	(2.3) 0	(‐) 1	(9.1) 0	(‐)
II 20	(48) 9	(38) 7	(64) 4	(57)
III 11	(26) 7	(29) 2	(18) 2	(29)
IV 9	(21) 8	(33) 1	(9.1) 0	(‐)
Extrahepatic	disease	at	diagnosis,	
n	(%)
14	(33) 7	(29) 4	(36) 2	(29)




30	(71) 23	(96) 7	(64) 0	(‐)
Cisplatin‐doxorubicin‐sorafenib 3	(7.1) 0	(‐) 3	(27) 0	(‐)
Ifosfamide‐vincristine‐based	
combinations
6	(14) 0	(‐) 0	(‐) 6	(86)
Doxorubicin‐vincristine 1	(2.3) 0	(‐) 0	(‐) 1	(14)
No	chemotherapy 2	(4.8) 1	(4.2) 1	(9.1) 0	(‐)
Definitive	surgical	management,	n	(%)
Resection 23	(55) 10	(42) 6	(55) 7	(100)
LT 13	(31) 9	(37) 4	(36) 0
































HCC	with	 vascular	 invasion	 and	extensive	portal	 vein	 thrombosis.	
Including	 the	 unoperated	 patients,	 the	 cumulative	 overall	 5‐year	
TA B L E  2  Comparison	of	HB	and	HCC	patients	managed	with	liver	transplantation	or	liver	resection
 
HB, n = 24 HCC, n = 11
Transplantation, n = 14 Resection, n = 10 Transplantation, n = 5 Resection, n = 6
Age	at	diagnosis,	years 2.1	(1.5‐4.1) 1.0	(0.36‐2.1) 11	(8.8‐13) 11	(8.3‐13)
AFP	at	diagnosis,	kU/la 360	000	(100	000‐1	200	000)b 59	000	(14	000‐180	000)b 9200	(2600‐32	000) 670	(33‐46	000)
PRETEXT,	n	(%)
I 0	(‐)b 0	(‐)b 1	(20)b 0	(‐)b
II 2	(14) 7	(70) 1	(20) 6	(100)
III 4	(29) 3	(30) 2	(40) 0	(‐)
IV 8	(57) 0	(‐) 1	(20) 0	(‐)
Extrahepatic	disease	at	
diagnosis,	n	(%)
5	(36) 2	(20) 0	(‐) 4	(67)
Local 3	(21) 1 10 0	(‐) 1	(17)
Distant	metastases 2	(14) 1	(10) 0	(‐) 3	(50)
Age	at	surgery,	years 3.9	(2.0‐6.7)b 1.2	(0.69‐2.4)b 12	(9.3‐14) 12	(8.8‐14)
Time	from	diagnosis	to	de‐
finitive	surgery,	months
6.8	(5.0‐13)b 2.4	(1.3‐3.9)b 7.4	(5.9‐7.6) 5.0	(4.7‐5.7)
Follow‐up	time	after	sur‐
gery,	years
8.5	(4.3‐17) 6.5	(2.7‐14) 10	(1.7‐15) 2.6	(0.39‐3.6)
Palliative	resection ‐ 0	(‐) ‐ 4	(67)
Residual	disease	after	definitive	surgery,	n	(%)
Local 0	(‐) 0	(‐) 0	(‐) 2	(33)
Distal 0	(‐) 0	(‐) 0	(‐) 1	(17)
Local	and	distal 0	(‐) 0	(‐) 0	(‐) 1	(17)
Recurrent	disease	after	definitive	surgery,	n	(%)
Local 0	(‐) 0	(‐) 0	(‐) 0	(‐)
Distal 3	(20) 0	(‐) 1	(20) 0	(‐)
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survival	 was	 80%	 (standard	 error	 8.2%)	 for	 HB	 and	 34%	 (stand‐
ard	 error	14%)	 for	HCC.	Altogether,	 42	patients	 underwent	 surgi‐
cal	management	for	their	malignancy	and	were	included	in	further	
analyses	(Table	1).
Prematurity,	 familial	 adenomatous	 polyposis	 and	 possible	
neonatal	 hemochromatosis,	 according	 to	 earlier	 accepted	 diag‐
nostic	 criteria,	 were	 associated	 disease	 states	 among	 five,	 two	
and	one	patient	with	HB,	respectively.	One	patient	with	chronic	
intrahepatic	 cholestasis	 leading	 cirrhosis	 and	 two	with	 possible	
neonatal	hemochromatosis	had	developed	HCC.	Of	patients	with	




line	 characteristics	were	 similar	 to	 other	 patients.	 Extrahepatic	
disease	 was	 present	 at	 diagnosis	 in	 four	 patients	 with	 HCC	
(36%)	as	well	 as	 in	 seven	patients	with	HB	 (29%),	of	whom	one	
had	PRETEXT	 I,	 four	PRETEXT	 III	and	 two	PRETEXT	 IV	disease	
(Tables	1	and	2).	Pulmonary	metastases	were	found	in	three	pa‐
tients	 with	 HB	 (13%),	 of	 whom	 two	 had	 PRETEXT	 III	 and	 one	
PRETEXT	 IV	 disease.	 Lung	 metastases	 were	 treated	 with	 che‐
motherapy	 in	 two	 patients	 and	 the	 remaining	 patient	 with	 re‐
section.	None	of	 the	 patients	with	HCC	 fulfilled	 the	University	
of	 California	 of	 San	 Francisco	 or	 the	 Milan	 criteria.19,20	 Apart	
from	one	patient	with	HB	(PRETEXT	II)	who	underwent	upfront	












Vascular	complications 4	(10) 4	(21) 0	(‐)
Biliary	complications 3	(7.1) 3	(16) 0	(‐)
Intra‐abdominal	infection 3	(7.1) 3	(16) 0	(‐)
Gastrointestinal	bleeding 2	(4.8) 1	(5.2) 1	(4.3)





Height	(z‐score) ‐0.45	(‐1.0‐1.0) ‐1.0	(‐2.0‐0.50) 0.20	(‐0.70‐1.4)




Disturbed	growtha,	n	(%) 4	(10) 4	(21)b 0	(‐)b
Liver	biochemistry	at	last	follow‐up
AFP,	kU/l 2.0	(1.7‐4.0) 3.0	(2.0‐4.0) 2.0	(1.0‐3.0)
Bilirubin, μmol/l 7.0	(6.0‐17) 14	(7.0‐23) 7.0	(6.0‐10)
ALT,	U/l 23	(17‐42) 34	(19‐41) 23	(16‐48)
Adverse	effects,	n	(%) 16	(38) 10	(53)b 6	(26)b
Transplant	rejection 5	(12) 5	(26) 0	(‐)
Sensorineural	hearing	loss 2	(4.8) 0	(‐) 2	(8.7)
Neuropathy 1	(2.4) 0	(‐) 1	(4.3)
Neutropenia 1	(2.4) 1	(5.2) 0	(‐)
Cardiomyopathy 3	(7.1) 2	(11) 1	(4.3)
ALL 1	(2.4) 0	(‐) 1	(4.3)
AML 2	(4.8) 1	(5.2) 1	(4.3)






TA B L E  3  Postoperative	complications	
and	follow‐up	characteristics	of	all	
surgically	treated	patients




Primary	 resections	 included	11	 right	hepatic	 lobectomies,	 five	ex‐
tended	right	hepatic	lobectomies,	two	left	hepatic	lobectomies,	one	
extended	 left	 lobectomy	 and	one	 left	 lateral	 segmentectomy	 (left	
trisegmentectomy).	 Patients	 with	 HB	 and	 HCC	 underwent	 liver	
transplantation	 or	 resection	 with	 relatively	 similar	 frequencies,	
while	 all	 patients	 with	 undifferentiated	 embryonal	 sarcoma	 were	





recurrence	 rates	 were	 comparable	 after	 primary	 and	 rescue	 liver	











     |  7TIUSANEN ET Al.
TA B L E  4  Univariate	analysis	of	5‐year	Kaplan‐Meier	overall	survival	of	surgically	treated	hepatoblastoma	patients	after	liver	malignancy	
diagnosis
Univariate
HB patients (n = 24)
Patients (n)
5‐year survival, %, 
mean (SE) P‐value Patients (n)
5‐year disease‐free sur‐
vival, %, mean (SE) P‐value
Management	before	2005
Yes 11 91	(9.0) .817 11 79	(13) .683
No 13 76	(16) 13 65	(18)
Age	at	diagnosisa,b
<High‐risk	age 21 88	(8.0) .090 21 81	(10) .290
≥High‐risk	age 3 67	(27) 3 33	(27)
Age	at	surgeryc
<2.4	years 12 100	(‐) .040 12 76	(15) .121
≥2.4	years 12 73	(13) 12 56	(15)
PRETEXT
I 0 ‐ .004 0 ‐ <.001
II 9 100	(‐) 9 100	(‐)
III 7 100	(‐) 7 100	(‐)
IV 8 60	(18) 8 31	(18)
Histologyd
Low	risk 9 76	(15) .460 9 76	(15) .926
Intermediate	risk 11 100	(‐) 11 63	(21)
High	risk 3 67	(27) 3 67	(27)
Vascular	invasion
Yes 17 80	(11) .490 17 58	(14) .327
No 7 100	(‐) 7 80	(18)
Extrahepatic	disease	at	diagnosis
Yes 7 100	(‐) .162 7 80	(18) .573
No 17 80	(12) 17 70	(13)
Risk	levela
Very	low 0 ‐ .552 0 ‐ .126
Low 2 100	(‐) 2 100	(‐)
Intermediate 10 83	(15) 10 83	(15)
High 11 81	(12) 11 56	(17)
Surgical	management
LT 9 76	(15) .265 9 65	(17) .067
Rescue	LT 5 80	(18) 5 38	(29)
Resection 10 100	(‐) 10 100	(‐)
Delay	from	diagnosis	to	definitive	surgerye
<4.9	months 12 100	(‐) .054 12 88	(11) .096
≥4.9	months 12 74	(13) 12 61	(15)
Any	surgical	complications
Yes 6 83	(15) .184 6 67	(19) .886
No 18 85	(10) 18 76	(13)
Recurrent/residual	disease	after	surgery
Yes 3 67	(27) .029 3 0	(‐) <.001
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3.4 | Outcomes of hepatoblastoma
Cumulative	 overall	 5‐year	 survival	 for	 operated	 patients	 with	 HB	
was	86%	(standard	error	7.8%)	and	5‐year	disease‐free	survival	73%	
(standard	error	11%).	All	patients	with	PRETEXT	II	and	III	survived,	
whereas	 the	cumulative	5‐year	 survival	 for	PRETEXT	 IV	was	60%	
(Figure	 1).	 Five	 out	 of	 the	 14	 transplanted	 patients	 with	 HB	 had	
undergone	 rescue	 liver	 transplantation	 either	 because	 of	 residual	




tases	were	managed	with	 chemotherapy	 in	 one	patient,	 resection	
in	 one	 patient	 or	 by	 both	 in	 one	 patient.	Disease	 recurrence	was	








3.5 | Outcomes of hepatocellular carcinoma
Five‐year	overall	survival	for	operated	patients	with	HCC	was	41%	
(standard	 error	 16%).	 The	 only	 factor	 predicting	 decreased	 sur‐
vival	 for	HCC	was	 recurrent	or	 residual	disease	 (0%	versus	83%,	
standard	 error	 15%,	P	 =	 .028),	whereas	 other	 patient	 character‐
istics	 such	 as	 histology,	 PRETEXT	 stage	 and	 age	were	 unrelated	
with	survival	(Figure	2).	Four	patients	with	disseminated	HCC	un‐
derwent	a	planned	palliative	resection.	The	patient	with	PRETEXT	
stage	 I	 HCC	 and	 underlying	 cirrhosis	 due	 to	 neonatal	 hepatitis	
underwent	 a	primary	 liver	 transplantation.	Residual	 extrahepatic	




none	of	 the	patients	with	 recurrent/residual	disease	survived.	 In	
addition,	one	patient	with	HCC	died	of	cardiomyopathy	after	suc‐
cessful	resection.
3.6 | Outcomes of embryonal carcinoma
Seven	patients	with	undifferentiated	embryonal	sarcoma	presented	
with	PRETEXT	stage	II	or	III	disease.	Of	them,	two	had	extrahepatic	

























one	of	the	 longest	follow‐ups	on	paediatric	 liver	malignancies.21,22 
Centralised	management	of	paediatric	liver	cancer	and	use	of	accu‐
rate	national	registry	data	enabled	reliable	calculation	of	incidence,	
recurrence	 and	 survival	 rates	 as	well	 as	 a	 detailed,	 long‐term	 and	
complete	 patient	 follow‐up.	 Our	 findings	 show	 encouraging	 long‐
term	survival	 for	HB	excluding	patients	with	PRETEXT	 IV	disease,	
which	 associated	with	 complications	of	 chemotherapy,	 recurrence	
and	decreased	survival	in	the	long‐term.
The	 incidence	of	HB	 is	 increasing	 in	 the	United	States	 and	 al‐
though	 an	 increase	 was	 also	 observed	 in	 Europe	 between	 1970s	
and	1990s,	 no	 similar	 trend	 exists	 in	more	 recent	 epidemiological	
studies.13,23,24	 Accordingly,	 our	 results	 demonstrate	 steady	 inci‐
dence	rates	of	1.1:106	for	paediatric	liver	malignancies	and	0.66:106 
for	HB	over	a	30‐year	 time	period,	 corresponding	a	 slightly	 lower	
incidence	for	HB	while	higher	for	HCC	when	compared	with	previ‐













overall	 and	disease‐free	 long‐term	survival	was	100%	 for	patients	
presenting	with	 lower	PRETEXT	stages,	 the	survival	outcomes	 for	
PRETEXT	 IV	 HB	 were	 markedly	 inferior	 although	 comparable	 to	
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larger	 contemporary	 reports.2,22	 As	many	 as	 one‐third	 of	 our	 pa‐
tients	with	HB	presented	with	either	PRETEXT	 IV	or	extrahepatic	
disease,	clearly	exceeding	the	proportions	of	such	high‐risk	patients	
















with	 HCC,	 no	 statistically	 significant	 predictors	 of	 survival	 apart	
from	recurrent	and	residual	disease	were	 identified.	Nevertheless,	
only	one	 liver	 transplantation	 recipient	with	HCC	experienced	 re‐
currence	 and	 died,	 supporting	 the	 benefit	 of	 liver	 transplantation	
for	children	with	inoperable	HCC	without	extrahepatic	involvement	
even	when	the	Milan	or	University	of	California	of	San	Francisco	cri‐









low‐up,	and	 larger	cohorts	are	needed	 to	evaluate	 their	benefit	 in	
paediatric	HCC.
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Our	 overall	 postoperative	 complication	 rate	 of	 33%	was	 com‐




planted	 for	 malignant	 than	 benign	 conditions.21,22	 In	 the	 present	
series,	 only	one	patient	was	 retransplanted	due	 to	 arterial	 throm‐
bosis	leading	to	biliary	necrosis.	Despite	the	low	rate	of	severe	op‐
erative	 complications,	 over	 one‐third	 of	 all	 deceased	 patients	 and	
half	of	deceased	patients	with	HB	died	of	adverse	effects	related	to	
chemotherapy	 or	 immunosuppression.	 Secondary	 cancer,	 possibly	
induced	by	the	use	of	alkylating	agents,	also	contributes	to	our	mod‐
est	5‐year	survival	of	67%	for	undifferentiated	embryonal	sarcoma.7 








The	 main	 limitations	 of	 this	 study	 included	 our	 inability	 to	
record	 reliably	 the	 exact	 cumulative	 dosage	 of	 chemotherapy,	
the	 low	number	 of	 patients	 due	 to	 rarity	 of	 childhood	 liver	ma‐





Apart	 from	PRETEXT	 IV	disease,	 the	national	 outcomes	 for	 sur‐
gically	 treated	 HB	 are	 encouraging.	 Outcomes	 of	 HCC	 and	 un‐
differentiated	embryonal	 sarcoma	are	 largely	determined	by	 the	
presence	of	extrahepatic	disease.	Diagnosing	paediatric	liver	ma‐
lignancies	at	earlier	stage	as	well	as	reducing	exposure	to	chemo‐
therapy	 appears	 challenging	 but	 attainable	 means	 to	 improve	
survival.
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